— For those on active therapy, 80% had increased antibody levels, study showed

by Mike Bassett

A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as these patients typically don’t produce antibody responses on par with healthy individuals.

One week after the administration of a third vaccine dose, neutralizing antibody responses improved in 80% of solid tumor patients undergoing chemotherapy, with adverse events that were mild in nature, reported Rachna T. Shroff, MD, MS, of the University of Arizona Cancer Center in Tucson, and colleagues.

Continue Reading Here



Submit a Comment

Find more articles